Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma

Targeting MAPK pathway using a combination of BRAF and MEK inhibitors is an efficient strategy to treat melanoma harboring BRAF-mutation. The development of acquired resistance is inevitable due to the signaling pathway rewiring. Combining western blotting, immunohistochemistry, and reverse phase pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Beike, Zhang, Wei, Zhang, Gao, Kwong, Lawrence, Lu, Hezhe, Tan, Jiufeng, Sadek, Norah, Xiao, Min, Zhang, Jie, Labrie, Marilyne, Randell, Sergio, Beroard, Aurelie, Sugarman, Eric, Rebecca, Vito W., Wei, Zhi, Lu, Yiling, Mills, Gordon B., Field, Jeffrey, Villanueva, Jessie, Xu, Xiaowei, Herlyn, Meenhard, Guo, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8445818/
https://www.ncbi.nlm.nih.gov/pubmed/34304249
http://dx.doi.org/10.1038/s41388-021-01911-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8445818/
https://www.ncbi.nlm.nih.gov/pubmed/34304249
http://dx.doi.org/10.1038/s41388-021-01911-5

Ejemplares similares